Physician profile
David Griffin
NPI 1023471901
$1,974.17
in general payments reported to CMS, 2019-2025
13 companies · $24.47 in 2025
The $24.47 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $163 · 2021: $313 · 2022: $168 · 2023: $234 · 2024: $574 · 2025: $24.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.48 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $814.94 | 2019-2025 | Hydrus Microstent, Clareon |
| Glaukos Corporation | $366.81 | 2019-2021 | |
| Sight Sciences, INC. | $178.00 | 2021-2024 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $159.70 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $119.26 | 2022-2024 | Stellaris, Envista Mx60 Iol |
| Rxsight INC | $118.40 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $77.84 | 2024 | |
| Novartis Pharmaceuticals Corporation | $35.90 | 2019-2021 | |
| Leadiant Biosciences, INC. | $25.57 | 2020 | |
| Kala Pharmaceuticals, INC. | $23.33 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $21.75 | 2021 | |
| Biotissue Holdings INC. | $16.93 | 2023 | |
| Omeros Corporation | $15.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.